Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients
暂无分享,去创建一个
T. Habuchi | M. Miura | S. Satoh | H. Kagaya | Toshio Suzuki | H. Tada | Y. Sagae | K. Inoue
[1] T. Habuchi,et al. Stereoselective metabolism of rabeprazole-thioether to rabeprazole by human liver microsomes , 2006, European Journal of Clinical Pharmacology.
[2] T. Habuchi,et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. , 2005, Transplantation proceedings.
[3] T. Habuchi,et al. Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers , 2005, Xenobiotica; the fate of foreign compounds in biological systems.
[4] T. Sakaeda,et al. Effect of rabeprazole on MDR1-mediated transport of Rhodamine 123 in Caco-2 and Hvr100-6 cells. , 2004, Biological & pharmaceutical bulletin.
[5] M. Miura,et al. Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[6] M. Kasuga,et al. CYP2C19 Genotype and Pharmacokinetics of Three Proton Pump Inhibitors in Healthy Subjects , 2001, Pharmaceutical Research.
[7] P. Beaune,et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[8] M. Homma,et al. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. , 2002, Transplantation proceedings.
[9] B. Ring,et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[10] E. Schuetz,et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. , 2002, Molecular pharmacology.
[11] J. Azuma,et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. , 2002, Pharmacogenetics.
[12] M. Kasuga,et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects , 2002, Clinical pharmacology and therapeutics.
[13] M. Homma,et al. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. , 2002, Transplantation.
[14] M. Haberl,et al. The genetic determinants of the CYP3A5 polymorphism. , 2001, Pharmacogenetics.
[15] M. Fromm,et al. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.
[16] C. Meisel,et al. Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects , 2001, Clinical pharmacology and therapeutics.
[17] J. Martorell.,et al. Mycophenolic Acid Plasma Concentrations: Influence of Comedication , 2001, Therapeutic drug monitoring.
[18] U. Brinkmann,et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[19] U. Klotz. Pharmacokinetic Considerations in the Eradication of Helicobacter Pylori , 2000, Clinical pharmacokinetics.
[20] T. Ishizaki,et al. Review article: cytochrome P450 and the metabolism of proton pump inhibitors — emphasis on rabeprazole , 1999, Alimentary pharmacology & therapeutics.
[21] T. Suzuki,et al. A rapid and simple detection of genetic defects responsible for the phenotypic polymorphism of cytochrome P450 2C19. , 1999, Biological & pharmaceutical bulletin.
[22] C. Nakamura,et al. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects , 1997, European Journal of Clinical Pharmacology.
[23] A. D. Rodrigues,et al. Identification of the human P450 enzymes involved in lansoprazole metabolism. , 1996, The Journal of pharmacology and experimental therapeutics.
[24] S. Binkley,et al. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. , 1996, Pharmacogenetics.
[25] U. Christians,et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[26] Kaoru Kobayashi,et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S‐mephenytoin 4′‐hydroxylation status , 1995, Clinical pharmacology and therapeutics.
[27] C. Bonfils,et al. Oxidative metabolism of lansoprazole by human liver cytochromes P450. , 1995, Molecular pharmacology.
[28] D. Dunn,et al. Incidence, complications, treatment, and outcome of ulcers of the upper gastrointestinal tract after renal transplantation during the cyclosporine era. , 1995, Journal of the American College of Surgeons.
[29] Y. Tanigawara,et al. Human P-glycoprotein transports cyclosporin A and FK506. , 1993, The Journal of biological chemistry.
[30] I. Yamatsu,et al. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione. , 1991, Biochemical pharmacology.
[31] H. Satoh,et al. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. , 1990, The Journal of pharmacology and experimental therapeutics.
[32] N. Takeguchi,et al. The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor. , 1990, Biochemical pharmacology.